Zydus gets FDA nod to market anti-fungal drug

The drug had estimated sales of around $92.8 million in 12 months to March 2016, as per IMS data

Ahmedabad-based Zydus Cadila has received the final approval from the US drug regulator USFDA to market Voriconazole tablets in strengths of 50 mg and 200 mg.

The drug, which is used for treatement of fungal infections, had estimated sales of around $92.8 million in 12 months to March 2016, as per IMS data.

Voriconazole will be produced at the group's formulations manufacturing facility at Baddi.

The group now has more than 100 approvals and has so far filed nearly 270 ANDAs since the commencement of the filing process in FY 2003-04.